Aaron Weitzman

'When a downturn comes, our portfolio will still be young, and we will not be managing 10-plus-year-old investments,' said EQT’s Eric Liu.

The influx of PE investment in drug development is 'great evidence of the need for capital solutions for the life sciences,' said NovaQuest’s Patrick Jordan.

Lovell Minnick Partners invests in London & Capital.

Happy Fri-yay, Hubsters! Aaron here on the Wire to end the week. This comment about dealmaking jumped out at me this week: “We are seeing a definite slowdown now, and I think the peak is behind us,” said Marco De Benedetti, co-head of Carlyle’s European private equity unit was being interviewed on Bloomberg TV. The interview […]

'Many of these segments within healthcare are a little bit more technical, and more complex, so our unique The Leaders Strategy approach pays real dividends there,' said GTCR's Cunningham.

Amy Margolis joins as managing director and head of business development and will focus on new deal origination and add-on acquisition sourcing.

The deal provides Centroid with additional data security technologies and expertise to enhance its end-to-end cloud transformation, consulting and managed services.

“EDI has a long history of innovation and leadership within the intersection safety market,” said Vance Street's Steve Sandbo.

This acquisition expands capabilities in interventional medical device product development and finished device assembly.

Happy Fri-yay dealmakers! Aaron here on the Wire. I don’t know about you, but it sure seemed like things picked up this week, and I am all for it! As the old cliché goes, “news never sleeps.” Well, there are some industries where that is not the case. But I think I speak for everyone […]